Free Trial

Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

Enanta Pharmaceuticals logo
$6.16 -0.12 (-1.91%)
(As of 09:56 AM ET)

Enanta Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
0
Buy
4

Based on 5 Wall Street analysts who have issued ratings for Enanta Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a sell rating, 3 have given a buy rating, and 1 has given a strong buy rating for ENTA.

Consensus Price Target

$19.50
216.56% Upside
According to the 5 analysts' twelve-month price targets for Enanta Pharmaceuticals, the average price target is $19.50. The highest price target for ENTA is $27.00, while the lowest price target for ENTA is $10.00. The average price target represents a forecasted upside of 216.56% from the current price of $6.16.
Get the Latest News and Ratings for ENTA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors.

Sign Up

ENTA Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$19.50$19.67$19.00$31.88
Forecasted Upside216.56% Upside110.56% Upside74.31% Upside248.36% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

ENTA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enanta Pharmaceuticals Stock vs. The Competition

TypeEnanta PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside210.51% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent ENTA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/26/2024Robert W. Baird
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$26.00 ➝ $20.00+138.66%
11/26/2024JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Outperform$22.00 ➝ $21.00+133.07%
10/10/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00+152.10%
8/6/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Bayko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$11.00 ➝ $10.00-22.66%
11/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$25.00 ➝ $21.00+128.76%
10/2/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform ➝ Sector Perform$25.00 ➝ $15.00+34.29%
8/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$49.00 ➝ $18.00-6.93%
2/9/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform$49.00-6.95%
2/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$87.00+59.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:15 AM ET.


ENTA Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Enanta Pharmaceuticals is $19.50, with a high forecast of $27.00 and a low forecast of $10.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ENTA shares.

According to analysts, Enanta Pharmaceuticals's stock has a predicted upside of 216.56% based on their 12-month stock forecasts.

Enanta Pharmaceuticals has been rated by research analysts at HC Wainwright, JMP Securities, and Robert W. Baird in the past 90 days.

Analysts like Enanta Pharmaceuticals less than other "medical" companies. The consensus rating score for Enanta Pharmaceuticals is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ENTA compares to other companies.


This page (NASDAQ:ENTA) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners